Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations.

Inclusion Criteria

- Male or female patients >= 18 years of age

- Pancreatic adenocarcinoma patients, previously diagnosed by biopsy, who are candidates

for intended curative resection either with or without neoadjuvant chemotherapy

- Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6

passes) of tumor and normal tissue for research purposes at the time of proposed

pancreatectomy

- 16 patients will be enrolled including 8 with no prior treatment and 8 treated with at

least 3 months of neoadjuvant chemotherapy

- All patients must be able to understand the investigational nature of the study and

give written informed consent prior to study entry

Exclusion Criteria

- Patients receiving any anti-cancer therapy (chemotherapy, immunotherapy, and/or

biologic therapy) for 8 patients; the other 8 patients will be treated with

neoadjuvant chemotherapy but no radiation, biologic or immunotherapy prior to surgery

- Is currently enrolled, or will enroll in, a different clinical study in which

investigational therapeutic procedures are performed or investigational therapies are

administered while participating in this study

- Concomitant active malignancy

- Is of child-bearing potential who has not had a recent negative pregnancy test done

outside of this clinical trial (i.e., as part of standard preparation for diagnosis

and treatment for her cancer)